Ewha Med J.  1996 Mar;19(1):139-143. 10.12771/emj.1996.19.1.139.

Effect of Thiotepa and BCG on Ta/Tl Bladder Tumors and Follow-up Rates

Affiliations
  • 1Department of Urology, Ewha Medical Research Center, College of Medicine, Ewha Womans University, Korea.

Abstract


OBJECTIVES
The efficacy and follow-up rate of intravesical therapy after transurethral resec-tion with thiotepa or bacillus Calmette-Guerin(BCG) for Ta/T1 transitional cell carcinoma of bladder was evaluated in 67 patients.
METHODS
After transurethral resection, thiptepa(60mg) or BCG(120mg, 5x108CFU/mg) was instillated into bladder every week. After 6 consecutive cycles were complicated, treatment results were evaluated with cystoscopy, urine cytology and biopsy of bladder mucosa. Disease free and follow-up rates were expressed with Kaplan-Meier curve and the treatment results were compared.
RESULTS
The effects of treatments were similar in both thiotepa and BCG groups. Overall, disease free rates at 1,2,3,4 and 5 years were 84, 72, 69, 65 and 42% respectively. Follow-up rates of the patients at the same periods were 55, 34, 28, 19 and 14% respectively. Mean time to progression to invasive cancer was significantly shorter than that of simple recurrence(p<0.05).
CONCLUSION
Intravesical therapy seems to be effective on the prevention of recurrence, re-gardless of the regimen of Ta/T1 bladder cancer. But the long term effect and the preventive role on progression of superficial bladder tumor should be established. In reality, the main lim-iting factor in the management of superficial bladder tumor is extremely high rate of follow-up loss.

Keyword

Bladder tumor; Thiotepa; BCG

MeSH Terms

Bacillus
Biopsy
Carcinoma, Transitional Cell
Cystoscopy
Follow-Up Studies*
Humans
Mucous Membrane
Mycobacterium bovis*
Recurrence
Thiotepa*
Urinary Bladder
Urinary Bladder Neoplasms*
Thiotepa
Full Text Links
  • EMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr